Cancer Network Staff

Hiba Siddiqui, BSc, of Dana-Farber discussed how targeting the CD44-SPP1 axis may overcome therapy resistance in muscle-invasive bladder cancer.

The ODAC has noted there was no clinical benefit of camizestrant for patients with HR+/HER2– advanced or metastatic breast cancer with ESR1 mutation and radiographic progression.

The FDA granted priority review to tislelizumab plus zanidatamab and chemotherapy for the first-line treatment of advanced HER2-positive gastric cancers.

Shikha Gupta, PhD, discussed the biology of tRCC and the mechanistic rationale behind combining CDK4/6 inhibition with selective mTORC1 targeting.

The conditional marketing authorization for tovorafenib in pediatric patients with low-grade glioma harboring a BRAF alteration is based on data from the FIREFLY-1 trial.

Alex Herrera, MD, analyzed the SWOG S1826 trial, highlighting how nivolumab plus AVD improved survival and reduced AEs in advanced Hodgkin lymphoma.

Updated interim data from a phase 1/2 study of the DR5 agonist ozekibart plus FOLFIRI demonstrated a 20% ORR and 87% DCR in late-line colorectal cancer.

New findings presented at the AACR Annual Meeting revealed risk factors for locoregional recurrence in patients diagnosed with breast cancer at age 40 or younger.

Key data from the ATLAS-IT-05 study showed the activity of the oncolytic peptide ruxotemitide plus pembrolizumab in refractory metastatic melanoma.

The FDA has granted fast track designation to BBO-11818, an investigational pan-KRAS inhibitor, for advanced KRAS-mutant pancreatic ductal adenocarcinoma.

Diane Simeone, MD, discussed efficacy results from the phase 3 RASolute 302 trial evaluating daraxonrasib in patients with metastatic pancreatic cancer.

Heath Skinner, MD, PhD, discussed current standards for radiotherapy in head and neck cancers and highlighted multidisciplinary collaboration within UPMC.

Zenocutuzumab has been added to the NCCN’s Clinical Practice Guidelines in Oncology for biliary tract cancers based on results from the phase 2 eNRGy trial.

Although ctDNA has limited utility in well-differentiated disease, it may have use in monitoring molecular residual disease in high-grade carcinomas.

The FDA has granted FTD and cleared an IND application for daretabart, an anti-GD2 monoclonal antibody, for the treatment of high-risk neuroblastoma.

Results from the phase 3 RASolute 302 trial showed that daraxonrasib improved median OS compared with standard chemotherapy in metastatic PDAC.

The FDA cited that the data provided for RP1 were insufficient and did not provide substantial evidence of effectiveness for this population.

The FDA has removed the partial clinical hold on the phase 2 LINNET study of lorigerlimab for patients with platinum-resistant ovarian cancer and clear cell gynecologic cancer.

The FDA has also approved the BD Onclarity HPV Assay for the screening of cervical cancer, with support from the SHIP trial evaluating at-home cervical cancer screening.

Treatment with Rhenium-186 Obisbemeda for pediatric malignant gliomas and ependymomas is being assessed in the ReSPECT-PBC trial.

The FDA granted fast track designation to SIM0505, a CDH6-directed antibody-drug conjugate, for the management of platinum-resistant ovarian cancer.

The FDA has granted orphan drug designation to tovecimig (CTX-009) for the treatment of bile duct cancer, following results from the phase 2/3 COMPANION-002 trial.

The 2026 ASCO thyroid cancer guideline update focused on the shifting landscape of systemic therapy for advanced disease.

Mina Fam, MD, explored the integration of multiparametric MRI and genomics in focal HIFU selection and compared its AE profile to radical intervention.

Robert Coleman, MD, FACOG, FACS, discusses the significance of the relacorilant and nab-paclitaxel approval in PROC supported by phase 3 ROSELLA trial data.

The FDA granted FTD to CTIM-76, a CLDN6/CD3 bispecific antibody, for the treatment of patients with CLDN6-positive platinum-resistant ovarian cancer.

Results from a phase 1/2a trial and the ongoing FORTE basket study support the FDA’s regulatory decision for these patients with recurrent or progressive glioma.

The phase 3 EMERALD-3 trial met its primary end point of PFS with durvalumab, tremelimumab, lenvatinib, and TACE in patients with unresectable HCC.

Management strategies for oxybutynin-induced xerostomia include hydration, sugar-free gum, and humidification.

BiliSeqV2/V3 improved neoplastic bile duct stricture identification compared with pathology alone, according to a study from UPMC investigators.